Cytokinetics, Inc. : Cytokinetics to Hold Annual Meeting of Stockholders

   Cytokinetics, Inc. : Cytokinetics to Hold Annual Meeting of Stockholders

South San Francisco, CA., May 15, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that its Annual Meeting of Stockholders will be held on
Tuesday, May 22, 2013 at 1:30 PM Pacific Time at the Embassy Suites Hotel,
located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum,
President and Chief Executive Officer, is scheduled to present an overview of
Cytokinetics' performance.

Interested parties may access the live audio webcast of this presentation  and 
replay by visiting the Investor Relations section of the Cytokinetics  website 
at www.cytokinetics.com.  The live  conference call  may also  be accessed  by 
dialing (866) 999-CYTK  (2985) (United  States and Canada)  or (706)  679-3078 
(international) and  typing in  the passcode  11891010. The  webcast will  be 
available via Cytokinetics'  website for  one week following  the event.  The 
replay of the audiocast will be available  via telephone from May 22, 2013  at 
2:30 PM Pacific  Time until  May 29, 2013  by dialing  (855) 859-2056  (United 
States and  Canada)  or  (404)  537-3406 (international)  and  typing  in  the 
passcode 11891010.

About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv and CK-2127107, both fast skeletal muscle activators, as
potential treatments for diseases and medical conditions associated with
aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently
the subject of a Phase II clinical trials program and has been granted orphan
drug designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the European
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis,
a debilitating disease of neuromuscular impairment in which treatment with
tirasemtiv produced potentially clinically relevant pharmacodynamic effects in
Phase II trials. All of these drug candidates have arisen from Cytokinetics'
muscle biology focused research activities and are directed towards the
cytoskeleton. The cytoskeleton is a complex biological infrastructure that
plays a fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.



Contact:
Cytokinetics, Incorporated 
Joanna L. Goldstein (Investors & Media)
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1702385
 
Press spacebar to pause and continue. Press esc to stop.